|
|
Article: NitroMed Announces Launch of BiDil(R) for the Treatment of Heart Failure in Black Patients; NitroMed Announces BiDil Pricing, BiDil Patient Assistance Program; July 15th Launch Overview Conference Call.
- Article from:
- Business Wire
- Article date:
- July 1, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LEXINGTON, Mass. -- NitroMed, Inc. (NASDAQ:NTMD) announced today that BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) is being launched for the treatment of heart failure in black patients as an adjunct to current standard therapies. BiDil was approved by the U.S. Food and Drug Administration (FDA) on June 23, 2005.
Today, NitroMed also announced BiDil pricing and its plans to implement a Patient Assistance Program (PAP) to ensure that BiDil is available to all patients who need it regardless of income level or health insurance status.
"NitroMed is pleased to be able to make BiDil available within one year of the African American Heart Failure ...